Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment modalities, alongside optimization of those already available, boldly continues. Each year, the ASH congress offers us the opportunity to learn about the latest developments in the MM field. This text aims to provide a brief summary of some of the latest insights presented at ASH this year.

(BELG J HEMATOL 2017;8(1):3–7)